Tempus Labs Inc.

SV Health Investors announced the final closing for its second Dementia Discovery Fund, DDF-2, with $269m in commitments from investors and non-profit organizations willing to put their money behind s

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

iRhythm Reveals Third DoJ Subpoena Wearable cardiac monitor company iRhythm Technologies, Inc. is facing a subpoena from the US Department of Justice’s Consumer Protection Branch, the company announ

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre